Immunohistochemicallocalization of P63 normal and proliferative conditions of the human prostate

The present study aimed at studying the immunoexpression of p63, the basal cell marker, in the normal human prostate gland and proliferative conditions. p63 was suggested as a valuable too/facilitating tile diagnosis of prostatic carcinoma and demarcating areas of transition from benign to malignant prostatic lesions. Human prostatic specimens were taken from patients with age range between 60- 70 years. The study was carried out on thirty-two prostate glands. Five were normal control prostates. Eleven prostatic specimens showed nodular prostatic hyperplasia [NPR], five of them exhibited cystic dilatation of its acini. Seven specimens partially presented NPH and partially expressed adenocarcinoma and nine specimens of prostatic adenocarcinoma. Prostatic sections were subjected to H and E staining and p63 immunohistochemical study. The optical density of p63 immunoreactive nuclei of busal cells of the human prostatic acini were assessed using image analysis. In the human prostatic acini, nuclei of the basal cells in the control group and cases of NPH were p63 immunoreactive. However, cases of NPH exhibiting cystic dilatation of acini, revealed a highly significant [P<0. 005] decrease in tile optical density of p63 immunoreactive nuclei of the basal cells versus the control group. Negative p63 inmunostaining was clearly noted in all cases of prostatic adenocarcinoma. Therefore, p63 can be considered as a useful tool that confirm the diagnosis of prostatic carcinoma especially in prostate needle biopsy

Expresión de los factores transformantes del crecimiento B2 y B3 en adenocarcinomas prostáticos / Expression of growth B2 and B3 transform factor in prostatic adenocarcinoma

Investigaciones llevadas a cabo sobre la biología y el desarrollo del carcinoma protático han constatado altos niveles de polipéptidos de TGF en el tejido prostático, así como las expresiones de las isoformas activas TGF-ß2, TGF-ß2 y Endoglina (CD105). Se revisaron 14 casos con diagnósticos de carcinoma prostático, durante el período comprendido entre enero de 1992a marzo del2001. Se obtuvieron datos clínicos de interés. Histológicamente, se tomó en cuenta el grado de histológico tumoral, la presencia de invasión perineural y/o vascular linfática. Del material incluido en parafina se realizó estudio inmunohistoquímico para antiTGF ß2, antiTGF ß3 y CD105.

Prostate specific antigen as tumor marker: relationship with histologic grading.

PSA is emerging as the best marker in oncology and had a profound impact on all aspects of prostate cancer care. From clinically suspected prostate tumor, 395 serum samples were taken out and estimated for serum PSA. Among elevated serum PSA, 98 were correlated with histologic findings. 42(42.8%) cases were BHP among 98 cases and 78.7% had serum PSA level within 10 ng/ml. 5 patients (5.1%) had PIN histologically, 3(60%) of which had PSA level upto 10 ng/ml and 2(40%) had serum PSA upto 20 ng/ml. 51(52%) were adenocarcinoma prostate of different grades and PSA level varies from less than 10 ng/ml to more than 50 ng/ml which almost correlates with the tumor grades.

Antígeno prostático específico: revisión de 80 pacientes / Serum prostate specific antigen: revision of the 80 patients

Se dosó Antígeno Prostático Específico en 80 pacientes con patología benigna y maligna de la próstata, durante los períodos pre y pos tratamiento. Se realizaron biopsias mapeadas de la próstata con biopty-gun, resecciones endoscópicas, ecografías abdominales y transrectales, prostatectomías radicales y orquidectomías, en aquellos pacientes que lo requirieron. Se trató de establecer el valor predictivo del PSA como método de screening, de estadificación y monitoreo de la respuesta al tratamiento médico o quirúrgico